Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study

Background: Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are frequently comorbid. Aims: To assess the effectiveness of vortioxetine in patients with MDD and comorbid GAD. Methods: Open-label, 8-week study (NCT04220996) in 100 adult outpatients with severe MDD and severe com...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychopharmacology (Oxford) 2022-05, Vol.36 (5), p.566-577
Main Authors: Christensen, Michael Cronquist, Schmidt, Simon, Grande, Iria
Format: Article
Language:English
Subjects:
Adult
Anxiety
Anxiety disorders
Anxiety Disorders - drug therapy
Anxiety Disorders - epidemiology
Comorbidity
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - epidemiology
Dosage
Generalized anxiety disorder
Humans
Mental depression
Original Papers
Patients
Quality of Life
Remission
Remission (Medicine)
Statistical analysis
Titration
Treatment Outcome
Vortioxetine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are frequently comorbid. Aims: To assess the effectiveness of vortioxetine in patients with MDD and comorbid GAD. Methods: Open-label, 8-week study (NCT04220996) in 100 adult outpatients with severe MDD and severe comorbid GAD receiving vortioxetine as first treatment for the current depressive episode or switching to vortioxetine due to inadequate response to another drug for depression. Vortioxetine starting dosage was 10 mg/day, with forced up-titration to 20 mg/day after 1 week. Response was defined as ⩾50% decrease in Montgomery–Åsberg Depression Rating Scale (MADRS) and/or Hamilton Anxiety Rating Scale (HAM-A) total score from baseline; remission defined as MADRS and/or HAM-A total score ⩽10. Results: Clinically meaningful and statistically significant improvements from baseline in symptoms of depression and anxiety, and overall functioning and health-related quality of life, were observed after 8 weeks’ vortioxetine treatment (all changes p 
ISSN:0269-8811
1461-7285
DOI:10.1177/02698811221090627